24.13
-0.65(-2.62%)
Currency In USD
| Previous Close | 24.78 |
| Open | 24.35 |
| Day High | 24.96 |
| Day Low | 24.13 |
| 52-Week High | 29.27 |
| 52-Week Low | 6.2 |
| Volume | 83,398 |
| Average Volume | 81,239 |
| Market Cap | 266.77M |
| PE | -11.6 |
| EPS | -2.08 |
| Moving Average 50 Days | 24.15 |
| Moving Average 200 Days | 18.65 |
| Change | -0.65 |
If you invested $1000 in Palvella Therapeutics, Inc. (PVLA) since IPO date, it would be worth $1,419.41 as of June 01, 2025 at a share price of $24.13. Whereas If you bought $1000 worth of Palvella Therapeutics, Inc. (PVLA) shares 0 years ago, it would be worth $1,419.41 as of June 01, 2025 at a share price of $24.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
Ms. Kline to lead Palvella’s commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estima
Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire Inc.
May 08, 2025 11:30 AM GMT
WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare
Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025
GlobeNewswire Inc.
May 05, 2025 11:30 AM GMT
WAYNE, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering fr